Médecins Sans Frontières has obtained an important but long-delayed victory in a a challenge to the refusal of the Medicines Control Council in South Africa to issue section 21 permission allowing the temporary importation and...
Read MoreMark Dybul, Executive Director of the Global Fund has written an email responding to a letter from 220 civil society organizations demanding that the Global Fund abandon its “tiered-pricing” proposal. His response:...
Read MoreBelow is a communication sent by Civil Society Organizations to Mark Dybul and others calling for the abandonment of the Global Fund’s misguided tiered-pricing initiative. The CS letter is attached. Dear Dr. Dybul, Dr....
Read MoreThis paper provides a detailed analysis of the effective geographical scope of the recently announced adult and pediatric between the Medicines Patent Pool and ViiV Healthcare covering dolutegravir. an important integrase...
Read MoreProfessor Brook K. Baker, Northeastern U. School of Law Policy Analyst Health GAP Full Paper – PDF On or about March 18, 2014, a third draft of the renamed “equitable access” proposal was released by Mark Dybul, Executive...
Read More[Brook Baker and Matt Kavanagh] Health GAP submits these comments in response to written and oral submissions made by PhRMA and other trade associations attacking India’s intellectual property regime, particularly its...
Read MoreThe US has evergreened its patent proposal requiring patents on new forms of known/existing medicines by requiring patents on medicines with “distinguishing features.” This is the wine of old IP maximalism – an...
Read MoreGilead is reported to be in talks to issue voluntary licenses to Indian generic manufacturers for the production of sofosbuvir, an important new drug to fight hepatitis C. If the intended territorial scope of licenses is only 60...
Read MorePhRMA (Pharmaceutical Researchers and Manufacturers of America) is putting $350,000 on the table to stop proposed patent law reform in South Africa and instead to lobby for even more monopoly protections for medicines. Why...
Read MoreOn December 11, the Medicines Patent Pool announced a new licensing agreement for a 2013 WHO recommended second-line antiretroviral, atazanavir (ATV). At this point, it is important for IP activists, generic companies, and...
Read MoreInside U.S. Trade (Nov. 27, 2013) has reported that the U.S. floated a non-paper proposal for differential treatment and a transition period for developing country partners (Vietnam, Peru, Mexico, and Malaysia) with respect to...
Read MoreInside US Trade[1] and the USTR[2] have announced that the U.S. is floating new proposals on IP in its marathon Trans-Pacific Partnership Agreement negotiations. Although the U.S. touts its new proposals as being balanced, as...
Read MoreInvestor-state dispute resolution is a growing concern for governments like Canada that should want to preserve policy space for regulating business activity. From licenses for fracking, mining, and timber cutting, to health...
Read MoreThe U.S. pharmaceutical industry and its Big Brother Chamber of Commerce have launched an all-out disinformation campaign against the India Patent Act and decisions rendered thereunder. They have enlisted allies in the U.S....
Read MoreThe Brazilian Center for Strategic Studies and Debates has just released the English version of its major report – Brazil’s Patent Reform: Innovation Towards National Competitiveness. This 363-page report comprehensively...
Read MoreAfter losing two patent cases before the appellate courts of a Western democracy, should a disgruntled foreign multinational pharmaceutical company be free take that country to private arbitration claiming that its expectations...
Read MoreThe U.S., acting on behalf of the U.S. biologics industries, will soon be trying to convince parties to the TPP that they should adopt extended data exclusivity for biologics (at least 12 years) as part of the intellectual...
Read More[UPDATE: Spanish version of the statement added July 21.] Activists and progressive health forces in Brazil have succeeded in catalyzing a proposal to reform Brazilian patent law to take advantage of key TRIPS flexibilities in...
Read MoreAs many of you may have heard, Brazil has been engaged in a long process of studying patent law reform and in August 2013 (originally scheduled for July 10, 2013) will be issuing a major report and proposed legislative reforms. ...
Read MoreOn June 18, 2013, 170 Members of Congress wrote to President Obama complaining about Indian trade policy and more particularly India’s intellectual property “climate.” Under the umbrella of claiming that...
Read More
Comments on: Civil Society Documents Comments on: industry | infojustice